Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27415734 | 0.82 | TDP1 (0.67) | TDP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL11819002 | 0.81 | TDP1 (0.64) | TDP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL29482300 | 0.80 | PDE10A (0.56) | TDP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL75026 | 0.80 | PDE10A (0.56) | TDP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL27932601 | 0.79 | TDP1 (0.62) | TDP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6595618 | 0.79 | TDP1 (0.62) | TDP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL9836130 | 0.79 | TDP1 (0.62) | TDP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL10549357 | 0.79 | TDP1 (0.62) | TDP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL619830 | 0.79 | TDP1 (0.62) | TDP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL29475175 | 0.79 | TDP1 (1.00) | TDP1ALDH1A1POLBNCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281126-B2 | Inhibitors of cyclin-dependent kinase 7 and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3617213-B1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-02-19 | — | — | EP | disclosed |
| CN-113557017-B | Inhibitors of cyclin-dependent kinase 7 and uses thereof | 丹娜-法伯癌症研究院 | 2024-11-29 | — | — | CN | disclosed |
| CN-118878514-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-115427394-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20220089611-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220064160-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (US) | 2022-03-03 | — | — | US | disclosed |
| EP-3902542-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-1228043-B1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2005-01-12 | — | — | EP | disclosed |
| EP-1373252-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002076975-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | WO | disclosed |
| EP-1233965-A1 | ISOQUINOLINE AND QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2002-08-28 | — | — | EP | disclosed |
| EP-1228043-A1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032659-A1 | ISOQUINOLINE AND QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
| WO-2001032626-A1 | ISOQUINOLINE AND QUINAZOLINE DERIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281126-B2 | Inhibitors of cyclin-dependent kinase 7 and uses thereof | CDK9, CDK7, CDK1 | TDP1 795/4885ALDH1A1 4202/4885KDM4E 3730/4885 |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | TDP1 2327/4885ALDH1A1 2328/4885KDM4E 2961/4885 |
| US-20220089611-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | CDK9, CDK7, CDK1 | TDP1 795/4885ALDH1A1 4202/4885KDM4E 3730/4885 |
| US-20220064160-A1 | BICYCLIC DERIVATIVES | FABP3, CYCS, PIGS | TDP1 4796/4885ALDH1A1 589/4885KDM4E 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.